Delayed trial readouts

Studies whose primary completion date moved on ClinicalTrials.gov in the last 180 days, newest first. The primary completion date is the sponsor's own estimate of when the last participant is assessed for the primary endpoint, so it is the nearest public marker of a readout. Our daily registry check records each move the day it sees it. Upcoming dates are on the readout calendar.

Summary

2,453 date moves: 1,669 later and 784 earlier. The median move later is 246 days.

Date moves

SeenDrugStudyPhaseOld dateNew dateMove
2026-11-20NMS-03597812NCT06549790Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid LeukemiaPhase 12029-09-152026-09-24−1087 days
2026-11-20PembrolizumabNCT06249048Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With PembrolizumabPhase 1/22027-052026-06-17−318 days
2026-11-20EsomeprazoleNCT06561542A Phase I Study of LX22001 for Injection in Healthy SubjectsPhase 12025-11-212025-01-23−302 days
2026-11-20Ferric derisomaltoseNCT05251493Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in PregnancyPhase 32026-12-312026-05-31−214 days
2026-11-20SelinexorNCT02227251Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Phase 22026-122026-06-02−182 days
2026-11-20BI 3000202NCT07774325A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the BloodPhase 12027-02-212026-10-11−133 days
2026-11-20ExemestaneNCT03125746A Study of LXI-15029 in Patients With Advanced Malignant Solid TumorsPhase 12021-10-282021-07-21−99 days
2026-11-20Xanomeline/trospium chlorideNCT07204418A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult ParticipantsPhase 12026-12-032026-09-28−66 days
2026-11-20PembrolizumabNCT03161431SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With PembrolizumabPhase 12026-082026-07-31−1 day
2026-11-20AR1001NCT03625622Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's DiseasePhase 22020-12-222020-12-21−1 day
2026-11-19NivolumabNCT05795244Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)Phase 22029-122026-02-24−1376 days
2026-11-19PregabalinNCT04322305Pregabalin Trial for the Treatment of Alcohol Use DisorderPhase 22025-06-302023-07-31−700 days
2026-11-19CRMA-1001NCT07200193A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis BPhase 1/22032-12-312031-02−699 days
2026-11-19tenofovir alafenamide (Vemlidy), Emtricitabine/tenofovir disoproxil fumarate, Lenacapavir (Sunlenca), BictegravirNCT06544733Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically SuppressedPhase 2/32028-012026-11-03−424 days
2026-11-19CadonilimabNCT05063916Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the CervixPhase 22027-08-012026-11-11−263 days
2026-11-19Methylprednisolone, abrocitinib, tofacitinibNCT06119490Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal NecrolysisPhase 12026-072025-10-14−260 days
2026-11-19PF-08634404, PembrolizumabNCT06980272SSGJ-707 in Advanced Non-Small Cell Lung CancerPhase 32026-07-302026-02-01−179 days
2026-11-19Tremelimumab, Olaparib, DurvalumabNCT03699449An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)Phase 22022-092022-05-17−107 days
2026-11-19NivolumabNCT04420975Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue SarcomaPhase 12027-01-312026-11-12−80 days
2026-11-19tilrekimigNCT07839884A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic Obstructive Pulmonary Disease (COPD) to Learn About This Medicine When Used for a Long Period of TimePhase 32034-05-122034-04-21−21 days
2026-11-19stapokibartNCT05728684Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related DiseasePhase na2024-02-282024-02-26−2 days
2026-11-18Tretinoin, PembrolizumabNCT06484920A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHLPhase 22027-122025-06-03−911 days
2026-11-18Ipilimumab, Nivolumab, tocilizumabNCT04940299Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaPhase 22027-12-312026-11-11−415 days
2026-11-18INCB123667NCT07214779Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 OverexpressionPhase 32028-11-152027-10-12−400 days
2026-11-18TemozolomideNCT04910022Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent GlioblastomaPhase 1/22027-05-302026-05-06−389 days
2026-11-18Gemcitabine, AtezolizumabNCT03775265Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder CancerPhase 32027-06-012026-07-23−313 days
2026-11-18Pembrolizumab, BlinatumomabNCT03512405Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic LeukemiaPhase 1/22025-11-112025-01-31−284 days
2026-11-18EntrectinibNCT02568267Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)Phase 22027-06-302026-10-29−244 days
2026-11-18TemozolomideNCT06931626Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung CancerPhase 12026-10-302026-08-20−71 days
2026-11-18ARV-806NCT07023731A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D MutationPhase 1/22026-11-302026-10-30−31 days
2026-11-18DepemokimabNCT07177339eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 InflammationPhase 32029-04-302029-04-02−28 days
2026-11-18InclisiranNCT07102628Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary SyndromesPhase 32027-02-112027-01-16−26 days
2026-11-18TafolecimabNCT07473960IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed HyperlipidemiaPhase 32026-09-062026-08-26−11 days
2026-11-18FelcorekibartNCT07915791A Study to Assess the Efficacy and Safety of Co-administration of GSK3862995B With GSK5784283 in Adult Participants With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)Phase 22029-03-162029-03-07−9 days
2026-11-17RamucirumabNCT06680622Bemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative ChemotherapyPhase 22027-092026-07-09−419 days
2026-11-17Dostarlimab, NiraparibNCT04068753Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix CancerPhase 22026-122026-08-06−117 days
2026-11-17Daraxonrasib, Nab-paclitaxel, GemcitabineNCT07491445Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaPhase 32028-062028-04−61 days
2026-11-17GFH276NCT07198321A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid TumorsPhase 1/22027-09-222027-07-30−54 days
2026-11-17AxatilimabNCT06132256MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)Phase 22026-092026-08-27−5 days
2026-11-14Oxycodone (Xtampza ER)NCT04659317Opioid-Free OrthopaedicsPhase 32028-122026-07-20−865 days
2026-11-14Elranatamab, Lenalidomide, DaratumumabNCT06931704Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)Phase 22030-11-302028-11-30−730 days
2026-11-14OrcaGraft (Orca-Q)NCT06900192A Multicenter Phase 1 Study of Orca-Q in Primary Progressive Multiple SclerosisPhase 12029-082028-06−426 days
2026-11-14pemetrexed, Adebrelimab, Nab-paclitaxelNCT05794477A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid TumorsPhase 1/22025-07-012024-08-20−315 days
2026-11-14metforminNCT04931017Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung CancerPhase 22026-12-312026-07-09−175 days
2026-11-14VosoritideNCT06668805A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone TreatmentPhase 22027-032026-09-16−166 days
2026-11-14BGM0504NCT06716203A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExercisePhase 32026-11-142026-08-13−93 days
2026-11-14BGM0504, Semaglutide (Ozempic)NCT06716216A Study of BGM0504 in Participants With Type 2 DiabetesPhase 32026-11-142026-08-25−81 days
2026-11-14maralixibatNCT06553768Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)Phase 32026-102026-07-29−64 days
2026-11-14Bempedoic acidNCT06780410A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic AcidPhase 32025-102025-08-05−57 days
2026-11-14BenralizumabNCT04565483Predictive Signature of Benralizumab ResponsePhase 42026-102026-08-19−43 days
2026-11-14EsketamineNCT05212571Long-term Pain Modulation by Intravenous Esketamine in CRPSPhase na2026-10-012026-08-20−42 days
2026-11-13IbrutinibNCT02787369ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLLPhase 12026-042019-06−2496 days
2026-11-13Ifebemtinib, FurmonertinibNCT05994131IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLCPhase 1/22026-07-312025-09-20−314 days
2026-11-13Naloxone (Narcan)NCT03616236Buprenorphine for Probationers and Parolees: Bridging the Gap Into TreatmentPhase 32026-08-312026-01-30−213 days
2026-11-13RituximabNCT06040320Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)Phase 1/22027-05-312026-11-06−206 days
2026-11-13Pelcitoclax, OsimertinibNCT04001777A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC PatientsPhase 12025-122025-05-27−188 days
2026-11-13BI 3000202NCT07486102A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver ProblemsPhase 12027-02-262026-10-30−119 days
2026-11-13SuzetrigineNCT07538570Evaluation of Pain Treatment After Total Knee ArthroplastyPhase 42027-01-302026-10-12−110 days
2026-11-13VosoritideNCT06455059Interventional Study of Vosoritide for the Treatment of Children With HypochondroplasiaPhase 32026-08-012026-04-23−100 days
2026-11-13tocilizumab, Iberdomide, ObinutuzumabNCT05169515A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin LymphomaPhase 12029-08-052029-04-30−97 days
2026-11-13BofanglutideNCT07144098Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver FunctionPhase 12026-07-122026-04-07−96 days
2026-11-13Erfonrilimab, Ifebemtinib, Nab-paclitaxel, GemcitabineNCT05827796IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic CancerPhase 1/22025-12-312025-10-11−81 days
2026-11-13tulisokibartNCT07133633A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)Phase 22027-06-152027-03-29−78 days
2026-11-13Semaglutide (Wegovy), survodutideNCT06745284A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With ObesityPhase 12027-01-082026-11-01−68 days
2026-11-13EsketamineNCT07625826The Effect of Esketamine on Cough Reflex During Tracheal Extubation in Patients Undergoing Open Thyroid SurgeryPhase na2027-052027-03−61 days
2026-11-13barzolvolimabNCT06455202A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)Phase 32026-102026-08-04−58 days
2026-11-13barzolvolimabNCT06445023A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous UrticariaPhase 32026-102026-08-12−50 days
2026-11-13BofanglutideNCT06728124A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight SubjectsPhase 32026-052026-03-26−36 days
2026-11-13MT-201NCT07219368A First-in-Human Single and Multiple Ascending Dose Study of MT-201Phase 12026-11-242026-10-20−35 days
2026-11-13Ifebemtinib, TislelizumabNCT06030258IN10018 Combination Therapy in Treatment-naïve ES-SCLCPhase 1/22025-12-242025-11-20−34 days
2026-11-13IfebemtinibNCT05551507IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian CancerPhase 1/22026-05-312026-05-11−20 days
2026-11-13precemtabart tocentecanNCT06806046Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid TumorsPhase 12026-09-302026-09-23−7 days
2026-11-13Dexamethasone, Elranatamab, Elotuzumab, Lenalidomide, Bortezomib, Pomalidomide, CarfilzomibNCT06152575MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)Phase 32026-08-302026-08-26−4 days
2026-11-13setmelanotideNCT05093634EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayPhase 32025-12-222025-12-19−3 days
2026-11-13Pegcetacoplan, BI 771716NCT06722157A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic AtrophyPhase 22026-10-282026-10-26−2 days
2026-11-11LuxdegalutamideNCT06991556An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Phase 22032-03-152026-12-03−1929 days
2026-11-11aldesleukinNCT04643574NeoTIL in Advanced Solid TumorsPhase 12027-112023-10-24−1469 days
2026-11-11elasomeranNCT04894435Mix and Match of the COVID-19 Vaccine for Safety and ImmunogenicityPhase 22024-11-152022-07-25−844 days
2026-11-11PelacarsenNCT05900141An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)Phase 32028-08-242026-10-15−679 days
2026-11-11DexamethasoneNCT07330999Three Variants of the PENG Block With and Without Perineural Adjuvants in Older AdultsPhase na2027-08-312026-05-20−468 days
2026-11-11BofanglutideNCT07292441Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight LossPhase 32027-092026-09-22−344 days
2026-11-11VebreltinibNCT07549061Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLCPhase 22028-05-302027-09-01−272 days
2026-11-11UlonivirineNCT07595263A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019)Phase 12027-01-152026-09-29−108 days
2026-11-11Nab-paclitaxel, BevacizumabNCT05075993Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid TumorsPhase 12027-02-022026-11-03−91 days
2026-11-11HiCM-188 (allogeneic iPSC-cardiomyocytes)NCT07646210HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass SurgeryPhase 1/22028-052028-02−90 days
2026-11-11Bofanglutide, Semaglutide (Ozempic)NCT06778967A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes MellitusPhase 32026-12-112026-09-18−84 days
2026-11-11Tirzepatide (Zepbound)NCT06162715GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot TrialPhase 2/32027-01-012026-10-10−83 days
2026-11-11Rosuvastatin, BofanglutideNCT07128888Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 InjectionPhase 12026-07-052026-04-13−83 days
2026-11-11Rifaximin (Xifaxan)NCT05677282Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide AdjunctPhase 42025-092025-06-29−64 days
2026-11-11Ranibizumab, BevacizumabNCT06952452Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)Phase 32026-072026-05-28−34 days
2026-11-11retatrutideNCT07232719A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightPhase 32027-072027-06−30 days
2026-11-11linaclotideNCT06692673Linaclotide for Colonoscopy Bowel PrepPhase 1/22026-04-302026-04-07−23 days
2026-11-11AfliberceptNCT06683742A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56Phase 32026-102026-09-09−22 days
2026-11-11Cabotegravir/rilpivirine (Cabenuva)NCT07650916A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically SuppressedPhase 32029-09-042029-08-13−22 days
2026-11-11remibrutinibNCT07855276A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HSPhase 12027-12-212027-11-29−22 days
2026-11-11AMG 691NCT07745907A Phase 1 Trial of AMG 691 in Healthy Chinese and Japanese VolunteersPhase 12027-03-312027-03-17−14 days
2026-11-11IbrutinibNCT03479268Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin LymphomaPhase 12026-11-052026-10-28−8 days
2026-11-11BofanglutideNCT06777238A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and ExercisePhase 32026-08-072026-07-30−8 days
2026-11-11VCT220NCT07340320A Study of CX11 Tablets in Patients With Type 2 Diabetes MellitusPhase 22027-04-162027-04-08−8 days
2026-11-11metreleptinNCT05164341Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PLPhase 32026-07-212026-07-14−7 days
2026-11-11Naloxone (Narcan)NCT07459166A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone BlockadePhase 22026-07-222026-07-15−7 days
2026-11-11ModafinilNCT07830056Modafinil to Optimize the Performance of Cold-Stressed Sleep-Deprived PersonnelPhase 42026-102026-09-24−7 days
2026-11-11rilzabrutinibNCT07216079Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in JapanPhase 32026-11-302026-11-25−5 days
2026-11-11lebrikizumabNCT01987492A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent AsthmaPhase 22016-12-202016-12-19−1 day
2026-11-10Ocrevus Zunovo, OcrelizumabNCT07667322A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple SclerosisPhase 12028-02-152026-09-01−532 days
2026-11-10tocilizumab, ObinutuzumabNCT04077723A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaPhase 1/22027-03-312026-12-28−93 days
2026-11-10NiraparibNCT04170153Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)Phase 12026-11-302026-10-14−47 days
2026-11-10ABBV-295NCT07514260A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.Phase 12027-012026-12−31 days
2026-11-10Dostarlimab, PembrolizumabNCT05565378A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerPhase 22026-11-092026-10-26−14 days
2026-11-10remibrutinibNCT07665437An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSPhase 32031-10-292031-10-15−14 days
2026-11-10Ruxolitinib (Opzelura)NCT06958211Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)Phase 32026-10-092026-10-01−8 days
2026-11-10Bevacizumab, AtezolizumabNCT05992220Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular InvasionPhase 22026-032026-02-25−4 days
2026-11-10tralokinumabNCT06311682A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic DermatitisPhase 32026-10-202026-10-16−4 days
2026-11-10VenetoclaxNCT06524375A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment PeriodPhase 22026-10-312026-10-28−3 days
2026-11-10Cabotegravir/rilpivirine (Cabenuva)NCT06786520A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy AdultsPhase 12027-03-092027-03-08−1 day
2026-11-08onabotulinumtoxinANCT07577310False Vocal Fold vs EMG Guided Botox for Vocal TremorPhase na2030-072028-07−730 days
2026-11-08DexamethasoneNCT07180940Comparison of Perineural Dexamethasone Versus Dexmedetomidine as Adjuvants to Erector Spinae Plane Block in Lumbar Spine SurgeryPhase 42026-09-302025-12-30−274 days
2026-11-08AvrukibartNCT07290569Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque PsoriasisPhase 22027-062026-10-21−223 days
2026-11-08CarfilzomibNCT05017545Carfilzomib and Belatacept for DesensitizationPhase 1/22027-02-282026-08-05−207 days
2026-11-08Rituximab, ObinutuzumabNCT05786768Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic SyndromePhase 2/32027-10-182027-06-30−110 days
2026-11-08enicepatideNCT07626515A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese ParticipantsPhase 12027-05-142027-04-08−36 days
2026-11-07OlaparibNCT05932862A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid TumorsPhase 12029-01-032027-04-30−614 days
2026-11-07DapagliflozinNCT07323524Dapagliflozin in Active Lupus NephritisPhase 42029-072028-07-01−365 days
2026-11-07TrontinemabNCT07717411A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's DiseasePhase 32032-09-032032-07-30−35 days
2026-11-07Cemdisiran, Pozelimab, Eculizumab, RavulizumabNCT05133531A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor TreatmentPhase 32026-10-122026-09-28−14 days
2026-11-07GSK3862995NCT06154837A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary DiseasePhase 12026-12-172026-12-16−1 day
2026-11-06Sacituzumab TirumotecanNCT06637423A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)Phase 1/22029-03-142026-09-30−896 days
2026-11-06Quetiapine (Seroquel), Clozapine, valproate, EsketamineNCT05603104Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment FailurePhase 32028-06-302026-06-24−737 days
2026-11-06CapecitabineNCT04703101Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal CancerPhase 12026-10-012025-07-03−455 days
2026-11-06Fulvestrant, IDE574NCT07540572A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid TumorsPhase 12030-03-302029-12-31−89 days
2026-11-06GabapentinNCT05443555Gabapentin to Reduce Alcohol and Improve Viral Load SuppressionPhase 22026-102026-09-24−7 days
2026-11-06Efimosfermin alfaNCT06920043A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASHPhase 22028-07-102028-07-03−7 days
2026-11-06Chiglitazar, metforminNCT07511010Food Effect and Multiple-Dose Study of Chiglitazar/Metformin Extended-Release TabletsPhase 12026-10-262026-10-22−4 days
2026-11-05Zoledronic acid, CapecitabineNCT03073785Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic CancerPhase 22027-122023-12-12−1450 days
2026-11-05Avutometinib/defactinib (Avmapki Fakzynja Co-Pack)NCT06104488A Study of Avutometinib for People With Solid Tumor CancersPhase 12029-10-202026-11-03−1082 days
2026-11-05zasocitinibNCT07244263A Study of Zasocitinib in Adults With Hidradenitis SuppurativaPhase 22028-02-222027-02-05−382 days
2026-11-05CapecitabineNCT05065957Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract CancerPhase 2/32026-072025-07-31−335 days
2026-11-05Beclomethasone dipropionate/formoterol fumarateNCT06515444Experimental Evaluation of a Program to Foster Socioemotional Competence of Children in Third Grade and Their TeachersPhase na2026-12-202026-08-01−141 days
2026-11-05HS-20118NCT06846710Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118Phase 12026-10-302026-07-14−108 days
2026-11-05DexamethasoneNCT07386600Dexamethasone vs Dexmedetomidine for iPACK + ACB in TKAPhase na2027-01-012026-09-30−93 days
2026-11-05Pembrolizumab, Nab-paclitaxel, Capecitabine, Gemcitabine, OlaparibNCT04753879Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.Phase 22026-07-012026-05-07−55 days
2026-11-05PembrolizumabNCT05296512Pembrolizumab and Lenvatinib in Clear Cell Ovarian CancerPhase 22026-09-232026-09-08−15 days
2026-11-05PembrolizumabNCT06308913Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell CarcinomaPhase 12026-102026-09-16−15 days
2026-11-05fluticasone propionateNCT06664619A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With AsthmaPhase 32026-11-022026-10-26−7 days
2026-11-04Gemcitabine, Fianlimab, CemiplimabNCT06571708Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)Phase 22028-122026-01-05−1061 days
2026-11-04jaktinibNCT05526222A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic DermatitisPhase 32026-062025-08-05−300 days
2026-11-04PembrolizumabNCT06005818Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC)Phase 22027-072026-10-01−273 days
2026-11-04zasocitinibNCT07108283A Study of Zasocitinib in Adults With Nonsegmental VitiligoPhase 22027-10-122027-03-26−200 days
2026-11-04Erfonrilimab, RegorafenibNCT05985109KN 046 Plus Regorafenib in MSS Metastatic Colorectal CancerPhase 22026-12-312026-09-30−92 days
2026-11-04Tobevibart (VIR-3434)NCT06903338A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV InfectionPhase 32026-12-312026-09-30−92 days
2026-11-04MethotrexateNCT04579848Methotrexate in Erosive Inflammatory Hand OsteoarthritisPhase 42026-122026-09-02−90 days
2026-11-04TeclistamabNCT06425991A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaPhase 12025-06-032025-04-21−43 days
2026-11-04fluticasone propionateNCT07597473Dymista in Chinese AdolescentsPhase 42026-102026-09-19−12 days
2026-11-04SetidegrasibNCT07773129A Study to Learn How ASP3082 is Processed in Healthy MenPhase 12026-10-312026-10-20−11 days
2026-11-04AZD4144NCT07685600Investigating the Effect of Itraconazole on the Pharmacokinetics of AZD4144 in Healthy ParticipantsPhase 12026-10-282026-10-22−6 days
2026-11-04Axitinib, PembrolizumabNCT05805501A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell CarcinomaPhase 22026-10-082026-10-05−3 days
2026-11-04JNJ-89853413NCT06618001A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic NeoplasmsPhase 12026-09-022026-09-01−1 day
2026-11-03Docetaxel, Gemcitabine, Eribulin mesylate, Sacituzumab GovitecanNCT04579224Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial CancerPhase 32030-08-152026-03-05−1624 days
2026-11-03adalimumabNCT02706704Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious UveitisPhase 22025-122022-01−1430 days
2026-11-03Entrectinib, Alectinib, DurvalumabNCT05170204A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)Phase 32030-06-162027-01-19−1244 days
2026-11-03Dexamethasone, Pomalidomide, IxazomibNCT02542657Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple MyelomaPhase 1/22025-082022-12-07−968 days
2026-11-03Obinutuzumab beta (Bejescin)NCT05796206A Phase 2 Clinical Study of MIL62 in Systemic Lupus ErythematosusPhase 22026-022024-11-21−437 days
2026-11-03LanifibranorNCT04849728A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )Phase 32027-09-302026-09-29−366 days
2026-11-03fingolimod (Gilenya)NCT04480853Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple SclerosisPhase 42027-09-302026-10-15−350 days
2026-11-03Axitinib, PembrolizumabNCT05363631Seleno-L Methionine (SLM)-Axitinib-PembrolizumabPhase 1/22026-12-312026-06-23−191 days
2026-11-03NivolumabNCT04652960Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary SyndromePhase 12026-12-032026-07-22−134 days
2026-11-03Nogapendekin alfa inbakicept (Anktiva)NCT04898543QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid TumorsPhase 12026-05-312026-02-02−118 days
2026-11-03MoponetugNCT06268886Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's DiseasePhase 22027-03-182026-12-17−91 days
2026-11-03DexamethasoneNCT05132920Fight INflammation to Improve Outcome After Aneurysmal Subarachnoid HEmorRhagePhase 32024-122024-09-09−83 days
2026-11-03onabotulinumtoxinANCT07756580A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar LinesPhase 12027-032027-02−28 days
2026-11-03Ramucirumab, PembrolizumabNCT04040361Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)Phase 22022-04-302022-04-20−10 days
2026-11-03Pembrolizumab, Nab-paclitaxelNCT05852691A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast CancerPhase 22026-10-192026-10-15−4 days
2026-11-01ToripalimabNCT06648200Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung CancerPhase 22030-09-012026-08-29−1464 days
2026-11-01Nab-paclitaxelNCT06115499The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic CancerPhase 2/32029-01-152027-12-01−411 days
2026-11-01NivolumabNCT05601752ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)Phase 22026-08-122025-09-30−316 days
2026-11-01Pembrolizumab, OlaparibNCT05093231Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic CancerPhase 22027-07-312026-11-30−243 days
2026-11-01Oxycodone (Xtampza ER)NCT04676802Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus OxycodonePhase 42027-022026-06-18−228 days
2026-11-01PembrolizumabNCT03371979Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung CancerPhase 1/22021-01-012020-06-11−204 days
2026-11-01CabozantinibNCT04876456A Phase II Trial of Cabozantinib With Patients With Refractory GCTsPhase 22027-012026-07-31−154 days
2026-11-01metforminNCT05781711Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's DiseasePhase 22025-01-202024-08-20−153 days
2026-11-01RAY1225NCT06254274A Study of RAY1225 in Participants With Type 2 DiabetesPhase 22025-12-202025-07-20−153 days
2026-11-01N-acetylcysteineNCT07803952N-Acetylcysteine in the Management of Spontaneous Bacterial PeritonitisPhase 1/22027-09-012027-06-01−92 days
2026-11-01Docetaxel, Gemcitabine, Risvutatug rezetecanNCT06935409Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment FailurePhase 32026-08-312026-06-17−75 days
2026-11-01PembrolizumabNCT07267338Pembrolizumab + MRGOO3 as Neoadjuvant in NPCPhase 22027-122027-10−61 days
2026-11-01Risvutatug rezetecanNCT06498479ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung CancerPhase 32026-09-302026-08-20−41 days
2026-11-01EpinephrineNCT07724418Split Face Study of the Duration of Local Anesthetics - Fifth ArmPhase 42027-06-302027-05-30−31 days
2026-11-01Brentuximab Vedotin, NivolumabNCT03712202Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin LymphomaPhase 22024-12-232024-11-30−23 days
2026-11-01DocetaxelNCT07711002Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)Phase 32031-06-172031-05-30−18 days
2026-11-01pemetrexed, Tislelizumab, Nab-paclitaxelNCT05635708A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung CancerPhase 22025-12-312025-12-19−12 days
2026-10-31tenofovir alafenamide (Vemlidy), Dolutegravir, RaltegravirNCT06337032A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsPhase 42034-032027-06−2465 days
2026-10-31Belinostat, TemozolomideNCT02137759MRSI to Predict Response to RT/TMZ ± Belinostat in GBMPhase 22023-08-152019-03-25−1604 days
2026-10-31VericiguatNCT05714085Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)Phase 2/32032-04-152029-08-20−969 days
2026-10-31CLN-978NCT05879744A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)Phase 12026-112024-06-01−883 days
2026-10-31Trastuzumab DeruxtecanNCT07022483A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant SettingPhase 32032-03-232030-02-26−756 days
2026-10-31lunsekimigNCT06914908Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical StudyPhase 22031-01-292029-02-22−706 days
2026-10-31Botensilimab, BalstilimabNCT05529316A Study of Botensilimab (AGEN1181) for the Treatment of Advanced MelanomaPhase 22028-022026-04-27−645 days
2026-10-31TadalafilNCT05195775Tadalafil as Adjuvant Therapy for DMDPhase 2/32025-09-052024-04-16−507 days
2026-10-31metforminNCT05553704Metformin in Patients With Ulcerative Colitis Treated With MesalaminePhase 22025-03-012023-12-01−456 days
2026-10-31Esketamine, PregabalinNCT07230171The Efficacy and Safety of Short Term S-ketamine Infusion as an Adjunctive Therapy in Patients With FibromyalgiaPhase na2027-06-302026-06-14−381 days
2026-10-31DapagliflozinNCT05792540Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive DisordersPhase 22024-11-202023-12-20−336 days
2026-10-31MethylprednisoloneNCT04163536Comparison of Corticosteroids vs Placebo on Duration of Ventilatory Support During Severe Acute Exacerbations of COPD Patients in the ICUPhase 32025-10-252024-11-24−335 days
2026-10-31GemcitabineNCT05701332Effect of Intravesical B.C.G and Gemcitabine on Semen Analysis and Testicular Volume in NMIBCPhase 42025-12-012025-01-18−317 days
2026-10-31tocilizumab, MethotrexateNCT03892785MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled TrialPhase 32027-012026-03-27−280 days
2026-10-31aldesleukinNCT04055623T-regulatory Cells in ALSPhase 22022-05-312021-08-31−273 days
2026-10-31DenifanstatNCT05743621Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate CancerPhase 12027-01-252026-05-12−258 days
2026-10-31Bevacizumab, AtezolizumabNCT03526432Phase II Study of Atezolizumab + Bevacizumab in Endometrial CancerPhase 22026-08-312025-12-19−255 days
2026-10-31VerteporfinNCT04590664Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated GlioblastomaPhase 1/22025-08-152025-02-13−183 days
2026-10-31DapagliflozinNCT07310433Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate CancerPhase 22029-10-302029-04-30−183 days
2026-10-31Capecitabine, TemozolomideNCT05247905Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET TrialPhase 22028-03-312027-10-01−182 days
2026-10-31remibrutinibNCT07855276A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HSPhase 12028-06-192027-12-21−181 days
2026-10-31SelinexorNCT03147885Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin LymphomaPhase 1/22027-122027-06-25−159 days
2026-10-31BudigalimabNCT06487559A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)Phase 12027-022026-09-18−136 days
2026-10-31Avelumab, Cemiplimab, Nivolumab, Atezolizumab, DurvalumabNCT06302426Trial of INI-4001 in Patients With Advanced Solid TumoursPhase 12026-10-302026-06-19−133 days
2026-10-31Nintedanib (Ofev)NCT03805477Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell TransplantationPhase 22026-122026-07-29−125 days
2026-10-31Ruxolitinib (Opzelura)NCT03954236Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host DiseasePhase 22027-02-062026-10-12−117 days
2026-10-31QuemliclustatNCT05329766A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract MalignanciesPhase 22027-012026-09-07−116 days
2026-10-31Docetaxel, GemcitabineNCT05644041Intravesical Gem/Doce in Patients With NMIBCPhase 22027-01-312026-10-19−104 days
2026-10-31CadonilimabNCT06508606AK117 (Anti-CD47 mAb) Plus Cetuximab as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaPhase 22026-11-012026-08-01−92 days
2026-10-31MethotrexateNCT05573555TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)Phase 1/22026-12-302026-10-06−85 days
2026-10-31Sacituzumab TirumotecanNCT06356311A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Phase 32027-01-042026-10-19−77 days
2026-10-31PomalidomideNCT07532525Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or LymphomaPhase 12027-102027-08−61 days
2026-10-31RademikibartNCT06488755SIM0718 Treatment of Asthma Clinical StudyPhase 32027-02-282026-12-31−59 days
2026-10-31BinimetinibNCT05564403Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)Phase 22026-10-012026-08-08−54 days
2026-10-31RanibizumabNCT06957080A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DMEPhase 2/32027-03-012027-01-11−49 days
2026-10-31Bevacizumab, AtezolizumabNCT04857684SBRT + Atezolizumab + Bevacizumab in Resectable HCCPhase 12026-04-292026-03-13−47 days
2026-10-31baricitinibNCT06240351A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)Phase 42026-10-312026-09-16−45 days
2026-10-31Gemcitabine, AtezolizumabNCT04630730Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBCPhase 22026-062026-04-26−36 days
2026-10-31Gemcitabine, ObinutuzumabNCT07711483GLORY: Glofit-GemOx With Liso-Cel For LymphomaPhase 22028-10-012028-09-15−16 days
2026-10-31LN-145NCT06566092Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult ParticipantsPhase 12026-072026-06-19−12 days
2026-10-31neflamapimodNCT06987643A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic StrokePhase 22026-09-302026-09-23−7 days
2026-10-31CemiplimabNCT05259709A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With CemiplimabPhase 12027-05-052027-04-29−6 days
2026-10-31VLS-01NCT06524830A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)Phase 22026-08-012026-07-30−2 days
2026-10-30ALTB-268NCT07350577Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy ParticipantsPhase 12026-09-262026-04-06−173 days
2026-10-30LigufalimabNCT06508606AK117 (Anti-CD47 mAb) Plus Cetuximab as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaPhase 22026-11-012026-08-01−92 days
2026-10-30Docetaxel, Zanidatamab, PertuzumabNCT07102381A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast CancerPhase 22028-01-012027-12-29−3 days
2026-10-29SCD-101NCT07401823Open-Label Extension Study to Pioneer Study 6058-SCD-101Phase 22030-02-042026-06-04−1341 days
2026-10-29DurvalumabNCT03999710Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung CancerPhase 22027-072026-10-20−254 days
2026-10-29AC-101NCT07083193A Study of AC-101 Tablets in Participants With Moderate to Severe Active Ulcerative ColitisPhase 1/22026-09-302026-04-20−163 days
2026-10-29TicagrelorNCT05681702Tailoring Bleeding Reduction Approaches in Patients Undergoing PCIPhase 42026-12-312026-08-05−148 days
2026-10-29tofacitinibNCT06393972The Efficacy and Safety of Tofacitinib in Patients With Glucocorticoid Resistant ICIs-related MyocarditisPhase 22025-11-302025-07-11−142 days
2026-10-29BortezomibNCT04268199A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home EnvironmentPhase 22026-122026-08-31−92 days
2026-10-29metforminNCT04407650Ursodeoxycholic Acid vs Metformin in Gestational Diabetes MellitusPhase 42024-12-312024-10-03−89 days
2026-10-29Palbociclib, Camizestrant, Ribociclib, AbemaciclibNCT06188520A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsPhase 1/22027-08-042027-06-30−35 days
2026-10-29Sevabertinib, metforminNCT07753252Phase 1 Study in Healthy Adults to See How Sevabertinib Changes Metformin Levels in the BodyPhase 12026-10-222026-10-06−16 days
2026-10-29Naloxone (Narcan)NCT07314346Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or MethadonePhase 12026-082026-07-23−9 days
2026-10-28dupilumabNCT07330934A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic DermatitisPhase 22027-06-302026-08-18−316 days
2026-10-28TarlatamabNCT07803848Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance StatusPhase 22027-12-312027-07-29−155 days
2026-10-28Vepdegestrant, RibociclibNCT05573555TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)Phase 1/22026-12-302026-10-06−85 days
2026-10-28IptacopanNCT05230537A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular DegenerationPhase 22026-09-302026-08-19−42 days
2026-10-28elasomeranNCT07863635A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsPhase 42027-01-092026-12-11−29 days
2026-10-28faricimabNCT06795048A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular DegenerationPhase 42026-10-202026-10-16−4 days
2026-10-27Empagliflozin, Liraglutide (Victoza)NCT04535960Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" TrialPhase 22023-102021-03-16−929 days
2026-10-27Patritumab DeruxtecanNCT03260491U3-1402 in Metastatic or Unresectable Non-Small Cell Lung CancerPhase 12026-03-312025-12-01−120 days
2026-10-27ALN-CIDEBNCT07631637Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 22029-02-062029-01-29−8 days
2026-10-26DurvalumabNCT04607954Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung CancerPhase 22026-09-012026-03-02−183 days
2026-10-26PembrolizumabNCT06302426Trial of INI-4001 in Patients With Advanced Solid TumoursPhase 12026-10-302026-06-19−133 days
2026-10-26PembrolizumabNCT05382325A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)Phase 12026-09-302026-09-29−1 day
2026-10-25Decitabine/cedazuridine (Inqovi)NCT06091267PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic SyndromesPhase 1/22026-05-312026-05-22−9 days
2026-10-24VY7523NCT06874621VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's DiseasePhase 1/22027-052026-10-13−200 days
2026-10-24QiShenYiQiNCT06006689Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)Phase 22025-09-012025-04-16−138 days
2026-10-24AficamtenNCT07023341A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic CardiomyopathyPhase 32026-08-312026-07-14−48 days
2026-10-24pemetrexedNCT04129502TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsPhase 32026-10-312026-09-22−39 days
2026-10-24InavolisibNCT07144111A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of InavolisibPhase 12026-11-162026-10-13−34 days
2026-10-24Cabotegravir/rilpivirine (Cabenuva)NCT06468995Antiviral Long Acting Drugs Landing in People Living With HIVPhase na2026-07-012026-06-19−12 days
2026-10-24Iparomlimab and tuvonralimab, BevacizumabNCT07416058PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLCPhase 22027-12-312027-12-30−1 day
2026-10-24SonrotoclaxNCT07628881A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy AdultsPhase 12026-09-272026-09-26−1 day
2026-10-23GemcitabineNCT06115499The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic CancerPhase 2/32029-01-152027-12-01−411 days
2026-10-23SunvozertinibNCT06295432A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)Phase 22026-122026-06-08−176 days
2026-10-23DocetaxelNCT06356311A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Phase 32027-01-042026-10-19−77 days
2026-10-23Dexamethasone, Lenalidomide, Bortezomib, DaratumumabNCT03591744Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell LeukemiaPhase 12019-10-252019-09-19−36 days
2026-10-22Dexamethasone, CT-P44, Lenalidomide, DaratumumabNCT06952478A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple MyelomaPhase 32027-11-152027-03-08−252 days
2026-10-22PembrolizumabNCT02977468Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast CancerPhase 12024-12-312024-07-18−166 days
2026-10-22Letrozole, Denosumab (Prolia)NCT06706414NT-NOA - Novel Treatment of Some Men With Non-Obstructive AzoospermiaPhase 1/22026-082026-04-30−93 days
2026-10-22CabozantinibNCT04412629Cabozantinib in High Grade Neuroendocrine NeoplasmsPhase 22026-09-302026-07-27−65 days
2026-10-22budesonide MMX (Uceris), BudesonideNCT05915104Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic ColitisPhase 22026-09-012026-07-27−36 days
2026-10-22Ribociclib, Trametinib, CetuximabNCT05358249Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationPhase 1/22026-09-302026-09-28−2 days
2026-10-21GDC-6988NCT06603246A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive DiseasePhase 12027-11-152026-08-18−454 days
2026-10-21Debecarasib, Cetuximab, Gemcitabine, Nab-paclitaxelNCT06586515MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid TumorsPhase 12029-032028-03−365 days
2026-10-21Docetaxel, ONO-4578, Ramucirumab, NivolumabNCT06542731An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Docetaxel and Ramucirumab as Second-line Therapy in Patients With Advanced or Recurrent Non-small Cell Lung CancerPhase 12026-09-122025-10-30−317 days
2026-10-21TovorafenibNCT07206849Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)Phase 22030-112030-02−273 days
2026-10-21SHR-1918NCT07349615A Study of SHR-1918 In Participants With HypertriglyceridemiaPhase 32027-112027-03−245 days
2026-10-21PembrolizumabNCT06551064Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma PatientsPhase 12026-06-302025-12-05−207 days
2026-10-21tulisokibartNCT07486960Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)Phase 22027-08-132027-02-17−177 days
2026-10-21MivelsiranNCT05231785A Study to Evaluate the Safety and Tolerability of ALN-APP in Patients With EOADPhase 12029-04-202029-01-11−99 days
2026-10-21Tamoxifen (Soltamox)NCT06361940Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast CancerPhase 22028-122028-09−91 days
2026-10-21Balcinrenone, DapagliflozinNCT07754331Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/DapagliflozinPhase 12026-12-032026-10-06−58 days
2026-10-21Dexamethasone, Isatuximab, LenalidomideNCT05690984Elimination of Minimal Residual Disease After TransplantPhase 22026-092026-08-19−13 days
2026-10-21BG-68501, Fulvestrant, BGB-43395NCT06257264A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsPhase 12026-08-312026-08-27−4 days
2026-10-20Tenofovir alafenamide/emtricitabine, DarunavirNCT06337032A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsPhase 42034-032027-06−2465 days
2026-10-20NivolumabNCT03854032Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and NeckPhase 22025-12-312022-02-10−1420 days
2026-10-20MethotrexateNCT05600426A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)Phase 32029-122026-08-06−1213 days
2026-10-20WTX-330NCT06939283A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or LymphomaPhase 1/22028-082026-04-23−831 days
2026-10-20Risvutatug rezetecan, DostarlimabNCT05277051First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsPhase 12027-08-312026-06-30−427 days
2026-10-20AfliberceptNCT07064759Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular DegenerationPhase 32028-112027-11−366 days
2026-10-20Ipilimumab, NivolumabNCT06365619Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable MelanomaPhase 22027-082026-10−304 days
2026-10-20dupilumabNCT06116526Dupilumab De-escalation in Pediatric Atopic DermatitisPhase 42027-04-012026-07-18−257 days
2026-10-20pemetrexed, PembrolizumabNCT04736173Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung CancerPhase 22027-052026-09-17−226 days
2026-10-20Olanzapine (Zyprexa), Insulin LisproNCT03741478Intranasal Insulin and Olanzapine Study in Healthy VolunteersPhase 12026-07-302026-06-01−59 days
2026-10-20BGM0504NCT07166081Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult SubjectsPhase 12026-05-132026-03-16−58 days
2026-10-17Azacitidine, VenetoclaxNCT04062266AZA + Venetoclax as Maintenance Therapy in Patients With AML in RemissionPhase 22030-10-312026-10-12−1480 days

Showing the newest 300 of 784 moves. Each drug page lists every registry date for its own studies.

Source: ClinicalTrials.gov, each study's record. A month-only date (YYYY-MM) is read as the first of the month, and a date that only gained or lost its day is not counted as a move. Every move we have recorded, not only the last 180 days, is a free CSV on the open data page.